Pipeline
Advancing predictive biology through a growing portfolio of immune intelligence applications.
The following table summarises each program's development stages across the 2026–2028 timeline. Stages are: Training (model development), Validation (clinical validation), and Regulatory Path (regulatory submission process).
| Program | Training | Validation | Regulatory Path |
|---|---|---|---|
| Immune Profiling | Q1 '26 – Q2 '26 | Q3 '26 – Q3 '26 | Q4 '26 – Q1 '28 |
| Crohn Disease Stratification | Q2 '26 – Q3 '26 | Q3 '26 – Q4 '26 | Q1 '27 – Q4 '28 |
| Immune Dysregulation Prediction | Q3 '26 – Q4 '26 | Q1 '27 – Q1 '27 | Q2 '27 – Q3 '28 |
| Sepsis Prediction for ER | Q3 '26 – Q1 '27 | Q1 '27 – Q2 '27 | Q2 '27 – Q4 '28 |
| Organ Transplant Rejection | Q3 '26 – Q1 '27 | Q1 '27 – Q2 '27 | Q2 '27 – Q4 '28 |
| Oncology Treatment Choice | Q4 '26 – Q1 '27 | Q1 '27 – Q2 '27 | Q3 '27 – Q4 '28 |
Future Directions
TeraCyte is building a growing portfolio of predictive biology applications powered by Temporal Cytometry™ and BioToken technology. Our pipeline spans immune profiling, disease stratification, clinical decision support, and treatment optimization, creating the foundation for the next generation of data-driven healthcare.